Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival—Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL
Nola M. Hylton(University of California, San Francisco), David C. Newitt(American College of Radiology), Paul T. Weatherall, Elizabeth A. Morris(University of California Davis Medical Center), Sandra M. Polin(Washington Radiology Associates), Constantine Gatsonis(Brown University), Etta D. Pisano(SUNY Sullivan), Laura J. Esserman(University of California, San Francisco), Mitchell D. Schnall(California University of Pennsylvania), Helga S. Marques(John Brown University), Constance D. Lehman(Harvard University), Gillian M. Newstead(University of Chicago), Mark Rosen(California University of Pennsylvania), Savannah C. Partridge(University of Washington), Wanda K. Bernreuter(University of Alabama)
Cited by 276
Related Papers
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
|CA A Cancer Journal for Clinicians|2007|2.6k
The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse
|Osteoarthritis and Cartilage|2007|1.5k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
|Journal of Clinical Oncology|2021|991